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An estimated 350 million people are living with chronic Hepatitis B virus (HBV) worldwide. Preventative HBV vaccination in infants has reduced the disease burden; however, insufficient immunization programs and access obstacles leave
vulnerable populations at risk for infection in endemic regions. Gene electrotransfer (GET) using a noninvasive multielectrode array (MEA) provides an alternative platform for DNA vaccination in the skin. DNA vaccines are nonlive and
nonreplicating and temperature stable unlike their counterparts. In addition, their simple engineering allows them to be
manufactured quickly at a low cost. In the current work, we present the combination of GET and moderate heating for
delivery of a DNA vaccine against HBV. Our laboratory has previously shown the synergy between moderate tissue
preheating at 43C and GET with the MEA as a means to reduce both the applied voltage and pulse number to achieve
similar if not higher gene expression than GET alone. In this study, we expand upon this work, by optimizing the plasmid
dose to achieve the highest level of expression. Using the reporter gene luciferase, we found that an intradermal injection
of 100 lL at 1 mg/mL induced the highest expression levels across all tested GET conditions. We then evaluated our
moderate heat-assisted GET platform for the intradermal delivery of a plasmid encoding Hepatitis B surface antigen
(pHBsAg) via a prime and prime plus boost vaccination protocol. At 18 weeks, following the prime plus boost protocol,
we observed that a high-voltage low-pulse GET condition with moderate heating (45 V 36 p+heat) generated antibodies
against Hepatitis B surface antigen (HBsAb) at peak measuring 230-fold over injection of plasmid DNA alone with
moderate heating. HBsAbs remained robust over the 30-week observation period. These data suggest that moderate heatassisted GET has the potential to induce strong immune responses, an attractive feature for development of an alternative
vaccine delivery platform.
Keywords: electrotransfer, DNA vaccine, gene delivery, electroporation, Hepatitis B, multielectrode array

INTRODUCTION
HEPATITIS B VIRUS (HBV) is a leading global cause of liver
disease.1–4 HBV infection is endemic in Asia, the Pacific
Islands, Eastern Europe, and sub-Saharan Africa where
most of the population are carriers.5–7 The virus is transmitted via blood or sexual contact and is quite resilient,
able to survive outside the body for up to 7 days. Each
year there are *20,000 new HBV cases in the US.8 The
symptoms of HBV infection are nonspecific, and infection is
generally confirmed through blood laboratory analysis once
latent indications appear. Preventative HBV vaccination has
reduced the disease burden; however, an estimated 350
million people worldwide are living with chronic HBV.9
Vaccination schedule compliance is critical for HBV
prevention. Current guidelines recommend beginning

vaccine dosing within 24 h of birth, followed by two to
three additional doses within the first year of life.10,11
Global vaccination estimates of children are unclear on
the extent to which vaccines are administered completely
and on time. In practice, vaccines tend to be given later
rather than earlier. When HBV vaccination is delayed,
children fail to receive adequate protection when they are
most vulnerable. Late vaccinations raise the risk of HBV
infection by lengthening the period of susceptibility. This
can have important implications in countries where HBV
infection is endemic, increasing the probability of transmission. In this situation, catch-up vaccination of older
children has relatively little impact for prophylaxis because infection may already have been acquired by the
time they present for vaccination. Vaccine compliance
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in endemic regions is related to access barriers. Limited
facilities, inadequately funded vaccination programs,
means and distance of travel to clinics, storage logistics,
and capacity hinder immunization coverage. The current
recommended HBV vaccine is recombinant protein consisting of the viral envelope protein Hepatitis B surface
antigen (HBsAb) and requires strict cold storage to maintain its stability.3,8–10
DNA vaccines are an attractive alternative to standard
vaccine types, given their innocuous make-up and simplicity of production requirements; however, there are
several pitfalls. Previous DNA vaccines in the clinical
pipeline have demonstrated poor cellular uptake and immunogenicity rendering them inconsistent or ineffective for
conferring protection. These shortcomings can be mediated
through enhanced delivery protocols beyond the standard
needle-fitted syringe administration. Delivery of plasmid
encoding viral antigen through gene electrotransfer (GET)
has potential as a DNA vaccination platform.12–17 A recent
clinical study delivering a DNA vaccine via GET showed
HBV-specific T cell responses in humans.18
In this work, we present a novel GET vaccine delivery
platform utilizing a combination of moderate heating and
noninvasive electrotransfer. We have previously shown the
advantages of combining electrotransfer with moderate
heating where both pulse number and applied voltage could
be significantly reduced resulting in a shorter and less painful
method.19,20 Futhermore, using the multielectrode array
(MEA) for intradermal delivery has been shown to be both
effective and tolerable.20–23 Minimizing discomfort is an
important consideration for translation to nonlife-threatening
applications such as vaccination, in which schedule compliance is critical to achieve immunization coverage.
Here, we present moderate heat-assisted GET for the
delivery of a DNA vaccine against HBV. To evaluate this
method, we utilized a guinea pig model for delivery of a
DNA vaccine encoding HBsAb. The objective of this work
was to determine the appropriate dosing and moderate heatassisted GET parameters for achieving elevated Hepatitis B
surface antibodies in circulation with the overarching goal
of conferring humoral immunity against HBV.

MATERIALS AND METHODS
Infrared laser system for moderate heating
Moderate heating was applied to maintain a surface
temperature of the treatment site at 43C. The moderate
heating and GET delivery is incased in a single device.
The heating system consists of a 980 nm wavelength infrared laser (Lasermate Group, Inc., Walnut, CA), an
optical fiber that delivers the infrared laser light to the skin,
and an emission splitter to distribute infrared laser light
through nine optical fibers, positioned between 16 conductive spring-loaded electrodes (Fig. 1).
For moderate heat application, the electrode was placed
with the spring-loaded GET electrode pins in contact with
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Figure 1. Moderate heat-assisted GET device. Moderate heating is performed via an infrared laser split into nine equally spaced fibers A–I positioned
in rows between the conductive MEA pins (black circles). GET is applied from
16 spring-loaded gold-plated round-tipped pins placed in contact with target
(gray circles). GET, gene electrotransfer; MEA, multielectrode array.

the skin, leaving a fixed distance of 8 mm between the
optical fibers and the vaccine target. The laser was applied
for a total of 30 s following injection of plasmid DNA.
This duration allowed for 43C to be maintained for 30 s
after removal of the moderate heating source (Edelblute
et al., Moderate heat-assisted GET as a potential delivery
approach for protein replacement therapy in the skin,
submitted; under review, 2021). The GET protocol was
*20 s in duration, enabling the tissue to remain heated
during its application. Moderate heating was always applied before and never concurrently with GET. Safety
precautions such as eyewear and barriers were in place
during all laser operations.
GET technology platform
The moderate heating and GET delivery was incased in a
single device for ease of use. The design of the MEA GET
delivery device has been previously described.22–24 In brief,
the electrode has 16 pins arranged in a 4 · 4 pattern at
2-mm-apart. Each pair of electrodes is programmed to administer either a train of 4 pulses with total 72 pulses or
2 pulses for a total of 36 pulses depending on pulsing conditions. The applied voltage was either 35 or 45 V between
two conductive pins, each with a pulse duration of 150 ms
and a 150 ms delay between pulses. Electrotransfer was
performed using the UltraVolt Model: Rack-2-500-00230
(Ultravolt, Inc., Ronkonkoma, NY).
Plasmids
For the initial dosing experiment, endotoxin-free plasmid
encoding the reporter gene firefly luciferase (gWizLuc) was
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commercially prepared at 2 mg/mL in 0.9% sterile injectable saline (Aldevron, Fargo, ND). For the HBV vaccination study, endotoxin-free plasmid encoding Hepatitis
B surface antigen (gWizHBsAg) was professionally prepared and suspended to 2 mg/mL in 0.9% sterile injectable
saline (Aldevron). Both plasmids have a gWiz backbone
and a human cytomegalovirus (pCMV) promoter.

Downloaded by Technion from www.liebertpub.com at 02/01/22. For personal use only.

Animals
Female guinea pigs aged 8-10 weeks weighing *350 g
were used for this study. Animals were housed at the ODU
AAALAC accredited animal facility and all procedures
were approved by the ODU IACUC protocol #17-022.
Animals were quarantined for 7 days before conducting
any procedure.
Moderate heat-assisted GET delivery
and plasmid dosing
Volume and concentration of plasmid DNA was first
assessed to determine the appropriate dose to achieve the
highest expression level with minimum adverse tissue
effects. For this experiment, we used a plasmid encoding
the reporter gene luciferase. Anesthesia was performed
by placing the animals in an induction chamber infused
with 3–4% isoflurane and 96–97% oxygen gas.
After animals were sufficiently anesthetized, they were
fitted with a standard rodent mask supplied with 3% isoflurane and oxygen to maintain a surgical plane of anesthesia. Animals were placed on a heating pad to ensure
thermoregulation during the entire procedure. Animals
were shaven and washed with mild soap (Dial) and water
in an outward circular motion to remove any loose hair or
an overabundance of oil. Injection sites were marked to
ensure accuracy of data collection. gWizLuc plasmid doses included volumes of 50 or 100 lL at 0.5, 1, or 2 mg/mL.
The electrode array was immediately positioned over the
injection area. When applicable, moderate heating was
always applied after injection, but before GET. The four
experimental groups included injection only (IO), injection
of pDNA followed by 72 pulses at 45 V (45 V 72 p), injection of pDNA followed by 72 pulses at 35 V with moderate heat (35 V 72 p+heat), and injection of pDNA followed
by 36 pulses at 45 V with moderate heat (45 V 36 p+heat).
Each experimental group was tested after injection of the
respective plasmid concentration and volume. Gene expression levels were measured 2, 5, 7, 9, and 14 days after
gene delivery via in vivo bioluminescence imaging.
In vivo bioluminescent imaging and kinetic
expression analysis
On days 2, 5, 7, 9, and 14, animals were anesthetized
with O2 containing 2.5–3.0% isoflurane followed by a
single subcutaneous injection of D-luciferin (Gold Biotechnology, St. Louis, MO) at 150 mg/kg administered at
the neck scruff. The animals were confined in an anes-

thesia chamber for 8 min then transferred to the IVIS
Spectrum (Perkin Elmer, Akron, OH), imaging chamber
under constant anesthesia. Regions of interest (ROI) were
selected on the resulting image to encompass the entirety
of each injection site independently. These results were
compared to untreated control ROIs. After background
correction, bioluminescence results were represented as
average total flux in photons/sec (p/s).
Moderate heat-assisted GET delivery
of plasmid encoding Hepatitis B
surface antigen
Female guinea pigs weighing *350 g were used for
this study as they represent a model for human skin. Anesthesia was performed as previously described. After
animals were sufficiently anesthetized, they were fitted
with a standard rodent mask supplied with 3% isoflurane
and 97% oxygen to maintain a surgical plane of anesthesia. The right flank was shaved and washed in the same
aforementioned manner, ensuring the removal of sebaceous oils before GET.
Moderate heat-assisted GET was applied after the
preoperative cleansing procedure. The five tested groups
included IO+heat (injection of plasmid without GET and
with moderate heating), plasmid encoding Hepatitis B
surface antigen (pHBsAg) +45 V 36 p (plasmid with highvoltage low-pulse GET), pHBsAg +45 V 36 p+heat
(plasmid with moderate heating and high-voltage lowpulse GET), pHBsAg +35 V 72 p (plasmid with moderate
heating and low-voltage high-pulse GET), and pHBsAg
+45 V 72 p (plasmid with high-voltage high-pulse GET).
pHBsAg was injected at a single site intradermally in a
100 lL volume at a concentration of 1 mg/mL (100 lg
total) immediately before moderate heating via infrared
laser or GET application.
Operating parameters for both moderate heating and
GET were delivered as previously described. After primary
vaccination, each animal was monitored continuously until
they recovered from anesthesia, as indicated by their ability
to maintain sternal recumbency and exhibit purposeful
movement. Boost vaccinations were administered 14 days
after the prime protocol in appropriate subjects in the same
manner, except on a different location on the animal’s flank.
Total HBsAg antibody production
An enzyme-linked immunosorbent assay (ELISA) kit
specific for guinea pig anti-HBsAg (KA0286; Novus
Biologicals) was used to detect anti-HBs in all animal
subjects. Sera was collected via a jugular vein puncture
and isolated in serum separator tubes, which were then
assayed per the manufacturers’ instructions. Serum was
collected 6, 11, 18, 24, and 30 weeks after immunization.
Sera collected before vaccination was used to determine baseline levels of circulating anti-HBs. Two standard deviations from the mean of this baseline served a
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positive result. Serial dilutions were performed on the
serum samples to accommodate these criteria. The results
are reported as HBsAb geometric mean titer.

Statistical significance between the groups for HBV
DNA vaccination was determined by two-way ANOVA
with a Tukey-Kramer multiple comparisons posttest
(GraphPad Prism Software). Results are expressed as the
mean of 5 individuals per group (–SEM). A p-value <0.05
was considered significant.

RESULTS
Increasing the volume of plasmid DNA,
not the concentration, yielded highest
expression levels
Plasmid DNA dosing was optimized by varying both
the concentration and intradermal injection volume at
each delivery site. For this work, the reporter gene

Downloaded by Technion from www.liebertpub.com at 02/01/22. For personal use only.

Statistical analysis
Statistical significance between groups for the reporter
gene dosing experiment was determined using a twoway analysis of variance (ANOVA) with a Tukey-Kramer
multiple comparisons posttest (GraphPad Prism Software, La Jolla, CA). Results are expressed as the mean of
4–8 replicates per group (–standard error of the mean
[SEM]). Significant results were determined with respect
to animals receiving injection of plasmid DNA alone
unless otherwise noted. A p-value <0.05 was considered
significant.
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Figure 2. Optimization of plasmid DNA dosing for moderate heat-assisted GET to the skin. Experimental groups included (A) injection pDNA only (IO), (B) 72
pulses at 35 V with moderate heat (35 V 72 p+heat), injection of pDNA followed by GET with (C) 36 pulses at 45 V with moderate heating (45 V 36 p+heat), or
(D) 72 pulses at 45 V without moderate heating (45 V 72 p). Plasmid DNA doses included volumes of 50 or 100 lL at 0.5, 1, or 2 mg/mL. Luciferase expression
levels reported as average total flux (photons/second) – SEM, n = 5–8 individual sites per group. IO, injection only; SEM, standard error of the mean.
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luciferase was used to determine the kinetics of luciferase
expression following the application of various pulsing
parameters with and without the addition of moderate
heat. Two volumes, 50 and 100 lL, and three concentrations, 0.5, 1, and 2 mg/mL, were evaluated across four
experimental conditions, including IO, moderately heated
GET conditions of 36 pulses at 45 V and 72 pulses at 35 V,
and ambient GET conditions of 72 pulses at 45 V.
Peak luciferase expression in vivo was observed 48 h
after exposure in all tested parameters and decreased gradually over the 2-week period of observation (Fig. 2). A
100 lL injection at 1 mg/mL yielded the highest overall
level of luciferase expression in all tested parameters compared to all other concentrations and volumes. The highest
expression was shown in those animals receiving 36 pulses
at 45 V with a total flux of 9.9 · 108 – 1.8 · 108 photons/s
after just 2 days (Fig. 2C). These results were significant
compared to injection of plasmid DNA alone ( p < 0.001)
(Fig. 2A). Similarly, 72 pulses at 45 V delivered at ambient
temperature following a 100 lL injection at 1 mg/mL resulted in a total flux of 8.84 · 108 – 5.66 · 108 photons/s
(Fig. 2D). However, this condition served as a positive
control, in that although expression levels were high, the
superficial damage attributed to these GET parameters were
unfavorable and negated its potential use for translation.

In the high-pulse, low-voltage moderately heated GET
condition (35 V 72 p+heat), the highest expression level
was also observed at day 2 with a total flux of 2.38 ·
108 – 2.82 · 107 photons/s after a 100 lL injection at
1 mg/mL (Fig. 2B). Although at a peak level lower than
that of the other tested GET conditions, these results
were significant with respect to those animals receiving
injection of plasmid DNA alone of the same volume
and concentration ( p < 0.01). Although not significant, on
observation days 7 and 9, animals receiving the higher
plasmid DNA concentration of 2 mg/mL in an injection
volume of 100 lL followed by 35 V 72 pulses plus moderate heating, displayed a trend of elevated expression
levels compared to the other five dosing parameters at the
same time point.
Moderate heat-assisted and ambient GET
induces the production of antibodies against
HBV surface antigen following intradermal
injection of pHBsAg
Circulating antibodies specific to HBV surface antigen
have been shown to be efficacious for conferring HBV
humoral immunity. Surveillance of HBsAb titer is used
clinically to determine if a follow-up boost vaccination is
warranted, as a drop in levels of this antibody suggests a

Figure 3. HBsAb production induced by moderate heat-assisted GET after a prime-boost DNA vaccination protocol against HBV. Prime and boost vaccinations were separated by 2 weeks. All animals received an intradermal injection of a pHBsAg in a 100 lL volume at 1 mg/mL. Experimental groups included
injection pDNA only plus moderate heating (IO+heat), injection of pDNA followed by GET with 72 pulses at 45 V (45 V 72 p), 72 pulses at 35 V with moderate heat
(35 V 72 p+heat), and 36 pulses at 45 V with (45 V 36 p+heat) or without moderate heating (45 V 36 p). Serum was collected via jugular vein puncture 6, 11, 18, 24,
and 30 weeks after immunization. Serum collected before vaccination was used to determine baseline levels of circulating HBsAbs. HBsAb titer in serum was
measured by ELISA. Two standard deviations from the mean of this baseline served as a positive result. Serial dilutions were performed on the serum samples
to accommodate these criteria. The results are reported as HBsAb geometric mean titer – SEM, n = 5 individuals per group. ***p < 0.001, **p < 0.01, *p < 0.05.
ELISA, enzyme-linked immunosorbent assay; HBsAb, Hepatitis B surface antigen; HBV, Hepatitis B virus; pHBsAg, plasmid encoding Hepatitis B surface
antigen.
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drop in immunization protection. The ability of moderate
heat-assisted GET to induce the production of HBsAbs
after injection of a plasmid encoding HBV surface antigen
was tested by comparing the levels of antibody titers in the
serum to unheated GET conditions. All GET parameters
had been previously tested for gene expression in the
dosing optimization experiment. Based on results from
the dosing experiment, an intradermal injection of 100 lL
at 1 mg/mL was used for this work.
GET parameters for DNA vaccination against HBV
included IO plus moderate heating, 45 V 36 pulses with
and without moderate heating, 35 V 72 pulses plus moderate heating, and 45 V 72 pulses without moderate heating. Guinea pigs were injected with pHBsAg followed by
appropriate GET and/or moderate heating conditions. A
boost vaccination was given in the same manner after 2
weeks at a different site than the prime. Serum collected
via the jugular vein over a 30-week observation period was
assayed using an ELISA.
Overall, HBsAb titers induced by DNA vaccination
with pHBsAg via all GET parameters, moderately heated
or ambient, were significantly higher than an IO control
with moderate heating. All GET groups displayed a
steady increase in antibody production, peaking at week
18 and waning gradually to the end of the observation
period. Notably, 45 V 36 pulses with moderate heating
yielded significantly higher HBsAbs titers compared to
all other tested conditions at all observation time points
( p < 0.001) (Fig. 3). By week 18, HBsAb titers in this
condition (45 V 36 p+heat) peaked and were 230-fold
higher than those in an IO control with moderate heating (IO+heat) ( p < 0.001). Furthermore, antibody production at week 18 in the experimental condition 45 V
36 pulses with moderate heating were 20-fold over
the HBsAb titer achieved by its ambient counterpart (45 V
36 p) ( p < 0.01).
Although our dosing experiment carried out with the
luciferase reporter gene indicated that expression levels
following GET with 45 V 72 pulses were similar to 45 V
36 pulses plus moderate heating, we did not observe
such similarities in HBsAb antibody production between these two treatments. Specifically at peak antibody production, 45 V 36 pulses with moderate heating
was still nearly 10-fold higher than the levels achieved
with 45 V 72 pulses delivered at ambient temperature
( p < 0.01).
Moderate heat-assisted GET elicits
significantly higher HBsAbs after both prime
and boost vaccination schedules
HBV DNA vaccination was evaluated after a single
primary dose to determine HBsAg antibody production at
a reduced schedule. For this work, we assessed efficacy
of the four previously tested GET groups: 35 V 72 pulses
with moderate heating, 45 V 72 pulses, and 45 V 36 pulses
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Figure 4. HBsAb production induced by moderate heat-assisted GET after
a prime only DNA vaccination protocol against HBV. No boost vaccination
was administered in this experiment. All animals received an intradermal
injection of a pHBsAg in a 100 lL volume at 1 mg/mL. Experimental injection
of pDNA followed by GET with 72 pulses at 45 V (45 V 72 p), 72 pulses at 35 V
with moderate heat (35 V 72 p+heat), and 36 pulses at 45 V with (45 V 36
p+heat) or without moderate heating (45 V 36 p). Serum was collected via
jugular vein puncture 6, 11, 18, 24, and 30 weeks after immunization. Serum
collected before vaccination was used to determine baseline levels of
circulating HBsAbs. HBsAb titer in serum was measured by ELISA. Two
standard deviations from the mean of this baseline served as a positive
result. Serial dilutions were performed on the serum samples to accommodate these criteria. The results are reported as HBsAb geometric mean
titer – SEM, n = 5 individuals per group. *p < 0.05.

with and without moderate heating. After the prime vaccination protocol, peak antibody production was observed
at week 6 across all tested GET parameters (Fig. 4). Just as
we observed after the boost vaccination, HBsAb titers in
those animals receiving pHBsAg followed by the highvoltage low-pulse moderately heated condition (45 V
36 p+heat) were significantly higher than all other
GET conditions. At week 6, HBsAb titers were 3-fold
higher in the experimental condition 45 V 36 pulses with
moderate heating compared to its ambient counterpart
(45 V 36 p) ( p < 0.05). Similarly, this condition was 1.73and 2.5-fold higher than 45 V 72 pulses without moderate heating and 35 V 72 pulses plus moderate heating,
respectively.
Overall, antibody production from the prime protocol
was far lower than those levels achieved from two doses:
a prime and boost given 2 weeks apart. However, although
a lower level of antibody production was observed, the
same trends between the tested GET parameters were
replicated in this experiment where 45 V 36 pulses plus
moderate heat induced the highest overall level of HBsAb
production.
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DISCUSSION
Whole-pathogen and subunit vaccines predominate
current vaccine schedules.25 Whole-pathogen vaccines
contain either killed or live-attenuated or weakened strains
that cannot cause disease, but are able to elicit an immune
response. Subunit vaccines comprised only the essential
antigens of a particular pathogen along with adjuvants to
achieve long-term immunity, as antigen alone is often not
enough to confer protection. Although effective, these
formulations require strict cold storage to maintain stability, are costly to manufacture, require multiple scheduled doses to achieve life-long protection, and can have
serious side effects in some recipients, such as those
with allergies or compromised immune systems, and in rare
cases can lead to reversion to a disease-causing state.25–27
DNA vaccines consist of a plasmid that carries genes
encoding proteins from the pathogen of interest.15,16 When
delivered, the plasmid enters host cells and serves as a
genetic template for the translation of its antigen. DNA
vaccines are nonlive and nonreplicating, leaving little
risk for secondary infection from vaccination. Due to
well-established production protocols, DNA plasmid
vaccines can be made rapidly, shortening the time between
an outbreak and the public health response. This streamlined approach is advantageous with the emergence of
new pathogens. DNA vaccines are an ideal global vaccination candidate due to their robust temperature stability, specificity to target antigen, and ease of large-scale
manufacturing. These advantages make DNA vaccines an
inexpensive option and therefore more feasible in lowincome regions where access to the general population is
a barrier.15
Reversible electroporation, where the cells survive, is
largely considered a nonthermal process. GET falls under
this category where a high-voltage pulse is applied creating
transient permeations in the cell membrane that are resealed
once the pulse is removed. Physical methods of GET28,29
are used both in vitro and in vivo and are well tolerated in
living tissues.18,30 By adding moderate heating to this approach, there is an increase in membrane fluidity allowing
for the widening of the transient permeations already
caused by GET.31,32 Thus, the interaction of moderate
heating and GET affords both a reduction in the necessary
pulse number and applied voltage to achieve a similar or
enhanced result.19,20 In practice, moderate heat-assisted
GET provides a faster and less painful delivery platform
with all the same benefits as ambient GET.
In the current work, we evaluated the use of moderate
heat-assisted GET for the delivery of a DNA vaccine
against HBV. Our initial testing to confirm plasmid dosing
allowed for more prudence in determining the proper
volume and concentration of plasmid to deliver in our
vaccination study. We found that a 100 lL injection at
1 mg/mL achieved the highest level of luciferase expres-

sion when followed by 45 V 36 pulses with moderate
heating. This is likely attributed to better coverage of the
plasmid DNA injection by the applied electric field and
exogenous moderate heating source, given that a 100 lL
injection measures *8 mm, while a 50 lL spans *5 mm.
Previous studies using reporter genes have determined that
a total concentration of 100 lg achieved the highest expression levels.19,20,33 Our results are in line with these data.
In all of our experiments, we chose to use 45 V 72
pulses as a positive control, which in our experience is a
MEA condition that reliably induces high expression
levels.16,17,19,20,22,24,34 However, we hypothesized that
this high-voltage high-pulse condition would not be suitable for translation due to observable skin damage caused
from its application (Edelblute et al., Moderate heatassisted GET as a potential delivery approach for protein
replacement therapy in the skin, submitted; under review,
2021). On this basis, we sought to reduce either the pulse
number and/or the applied voltage with the addition of
moderate heat to compensate for expression loses all the
while maintaining tissue health.
Tissue health is critical for reversible electroporation
approaches such as GET, where live cells are needed to
achieve gene expression in the host. Furthermore, in
nonlife threatening applications such as vaccination visible scarring and pain at the delivery site are unappealing
side effects. These could be overlooked in some cases,
where the benefit outweighs the detriment of the side effect, but it is not ideal. We found that with the addition of
moderate heat, we were able to reduce the applied voltage
by 23% and the pulse number by 50% all the while
achieving a similar luciferase expression level and eliminating the tissue damaging side effects.
For the delivery of a DNA vaccine against HBV, we
evaluated both a prime and a prime plus boost vaccination
protocol. We found that GET parameters of 45 V 36 pulses
with the addition of moderate heat far exceeded the serum levels of HBsAbs produced by any of the other GET
conditions we tested in both the prime and prime plus boost
vaccination protocols. These levels were especially elevated
in those animals receiving the prime plus boost vaccination
schedule and remained stable during the entire 30-week
observation period. This suggests that the effects of moderate heat-assisted GET with respect to antibody production
are long lasting. Vaccine longevity is just as critical as
compliance, so these results are encouraging.
Furthermore, all of the GET conditions we evaluated
induced significant HBsAb production compared to injection of pHBsAg alone. Interestingly, although the highvoltage high-pulse condition (45 V 72 p) showed similar
expression levels in our reporter gene experiment, this did
not translate to high antibody production in our vaccination study. This could imply that the tissue damage induced by these delivery parameters is too severe to achieve
a robust antibody response, where the inflammation at the
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target site is being addressed at a greater magnitude than
HBsAg uptake and antigen presentation to mediate the
generation of HBsAg antibodies. While in the moderately
heated low-voltage, high-pulse condition (45 V 36
p+heat), no gross skin damage was observed, and total
antibody production was thus higher.
The results of the prime vaccination protocol followed
the same trend as the prime plus boost protocol, just at a far
lower magnitude. We still observed that GET parameters
of 45 V 36 pulses with moderate heating induced the
highest level of HBsAb production compared to the other
tested GET conditions. These results suggest that prime
vaccination alone can prompt enduring antibody production in this case, although the prime plus boost protocol
was far more robust and more likely to confer long-lasting
protection. These data were important to collect, as vaccine schedule compliance is a concern among both patients
and physicians. It was therefore important to determine the
total HBsAg antibody production in a prime only vaccination protocol, although we suggest in this case the prime
boost vaccination protocol would be more effective.
An effective vaccine capable of producing sustained
protective antibody titers could eliminate the need for
multiple booster vaccinations, an appealing solution for all
parties. The current vaccination schedule for HBV in infants recommends a series of three shots: shortly after
birth, aged 1–2 months, and 6–18 months.2,10,11 Our prime
boost vaccination protocol consisted of two doses; with
antibody titers in our highest GET expressing condition,
45 V 36 pulses with moderate heating, decreasing after
30 weeks. It is therefore likely that additional booster
vaccinations may be necessary to prolong HBV protection.
Moderate heating increased the overall expression
levels achieved by intradermal GET applied at ambient
temperature. Moreover, using moderate heat allows for
greater penetration depth for the applied electric fields,
creating a situation where the uptake of plasmid DNA by
professional antigen presenting cells such as dendritic
cells is more likely.30,35,36 This is an essential aspect of
an effective vaccine, mediated by both the cellular and
humoral immune systems and dependent upon the specificity for the plasmid-encoded antigen.30,35–38 Where we
have historically viewed an intradermal delivery platform as confined to the epidermis and dermis, with the
addition of moderate heating, it could be possible for
aqueous delivery via cutaneous GET to the hypodermis and
muscle tissues (Edelblute et al., Moderate heat-assisted
GET as a potential delivery approach for protein replacement therapy in the skin, submitted; under review, 2021).
The long-lasting HBsAg antibody production we observed after DNA vaccination in our moderately heated
GET condition (45 V 36 p+heat) is evidence that muscle
delivery with an intradermal approach is not only possible, but also more than likely occurring. This is favorable, as
most vaccines require muscle delivery, although it is un-
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clear if their administration is precise as muscle is an underlying unseen tissue that is not so easily monitored.
In addition, intramuscular vaccinations typically administered in the deltoid muscle can cause upper arm injury,
bursitis, or other shoulder dysfunctions if not carefully
administered.39–42 In infants, intramuscular vaccinations are
given in the vastus lateralis located in anterolateral thigh.
This site has been deemed the safest intramuscular route,
although the middle of the muscle should be the target, not
the upper or lower portion, as its adjacency to the muscle
branch of the femoral nerve and the lateral circumflex
femoral artery.40,43,44 Intradermal delivery by contrast is
visible and therefore easier to ensure correct administration.
With moderate heat-assisted GET, there are the advantages
of muscle delivery with an intradermal approach.
We have previously shown the utility the MEA device for DNA vaccination with a plasmid encoding
protective antigen against Bacillus anthracis in a murine model as well as for delivering the same plasmid
administered in this work against HBV.16,17 Here, we
expand upon this original platform and present moderate heat-assisted GET as a novel method with a reconfigured device for intradermal DNA vaccination.
Our preliminary results demonstrate that moderate heatassisted GET yields a significantly higher and longer
duration of expression compared to needle-fitted syringe
injection alone in vivo.
We selected HBV to evaluate our novel delivery platform because it is a well-characterized vaccination model.
Previous reports have shown HBsAg geometric mean titers in correlation with HBV protective efficacy in mice,
rats, guinea pigs, woodchucks, and sheep.45–47 This suggests that the high HBsAg antibody titers we were able
to generate with moderately heated GET to signify humoral immunity would also be in the protective range,
as our numbers are in line with these reports. As a proof
of principle, we show enduring antibody production
against HBV in vivo over a period of 30 weeks following
moderate heat-assisted GET.
Compared to our original work, adding moderate heat
to GET induced antibody production nearly 8-fold over
GET using the MEA at ambient temperature.17 These
results indicate the synergy between moderate heat and
GET to enhance gene delivery in the skin. Future work
should involve characterizing the cellular immune response induced by this approach and a challenge experiment to confirm its protective effects against HBV.
Also, these results warrant the consideration of additional vaccinations utilizing plasmid-encoded antigens
delivered via moderate heat-assisted GET.
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